Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Heeg

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Hepatology (Baltimore, Md.)|May 22, 2012
Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activityMaximilian Heeg, Robert Thimme
Immunological Reviews|May 16, 2023
Insights into phenotypic and functional CD8<sup>+</sup> T<sub>RM</sub> heterogeneityMaximilian Heeg, Ananda W Goldrath
The Journal of Experimental Medicine|March 10, 2023
License to kill: Retinoic acid programs T cells for tissue residencyMaximilian Heeg, Ananda W Goldrath
Biomedical Journal|August 9, 2021
Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotypeLaura Faletti, Stephan Ehl, Maximilian Heeg
Clinical Science (London, England : 1979)|September 28, 2012
Hepatitis B virus: from immunobiology to immunotherapyDaniel Grimm, Maximilian Heeg, Robert Thimme
Journal of Clinical Immunology|May 4, 2023
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional ConsequencesNils Ott, Laura Faletti, Maximilian Heeg, et al.
Clinical Immunology (Orlando, Fla.)|June 14, 2019
Profound immunodeficiency with severe skin disease explained by concomitant novel CARMIL2 and PLEC1 loss-of-function mutationsMaria E Maccari, Carsten Speckmann, Maximilian Heeg, et al.
Plos Pathogens|September 13, 2012
OX40 facilitates control of a persistent virus infectionTobias Boettler, Friedrich Moeckel, Yang Cheng, et al.
European Journal of Immunology|December 8, 2016
Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoireSandra Ammann, Kai Lehmberg, Udo Zur Stadt, et al.
Pediatric Blood & Cancer|August 3, 2018
Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal diseaseMaximilian Heeg, Sandra Ammann, Christian Klemann, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|May 22, 2012
Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activityMaximilian Heeg, Robert Thimme
Immunological Reviews|May 16, 2023
Insights into phenotypic and functional CD8<sup>+</sup> T<sub>RM</sub> heterogeneityMaximilian Heeg, Ananda W Goldrath
The Journal of Experimental Medicine|March 10, 2023
License to kill: Retinoic acid programs T cells for tissue residencyMaximilian Heeg, Ananda W Goldrath
Biomedical Journal|August 9, 2021
Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotypeLaura Faletti, Stephan Ehl, Maximilian Heeg
Clinical Science (London, England : 1979)|September 28, 2012
Hepatitis B virus: from immunobiology to immunotherapyDaniel Grimm, Maximilian Heeg, Robert Thimme
Journal of Clinical Immunology|May 4, 2023
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional ConsequencesNils Ott, Laura Faletti, Maximilian Heeg, et al.
Clinical Immunology (Orlando, Fla.)|June 14, 2019
Profound immunodeficiency with severe skin disease explained by concomitant novel CARMIL2 and PLEC1 loss-of-function mutationsMaria E Maccari, Carsten Speckmann, Maximilian Heeg, et al.
Plos Pathogens|September 13, 2012
OX40 facilitates control of a persistent virus infectionTobias Boettler, Friedrich Moeckel, Yang Cheng, et al.
European Journal of Immunology|December 8, 2016
Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoireSandra Ammann, Kai Lehmberg, Udo Zur Stadt, et al.
Pediatric Blood & Cancer|August 3, 2018
Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal diseaseMaximilian Heeg, Sandra Ammann, Christian Klemann, et al.
Pageof 5